Allergan expands Refresh eye treatment portfolio
A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.
Allergan has launched three new over-the-counter (OTC) Refresh Relieva products: Refresh Relieva; Refresh Relieva PF (preservative-free) multidose; and Refresh Relieva for Contacts.
This new line of artificial tear formulations available in preserved, preservative-free multidose, and a formula designed for contact lens wearers, are specially formulated to relieve discomfort due to eye dryness and to prevent further irritation. Refresh, a doctor recommended brand of artificial tears, continues to expand its portfolio by offering the only family of products in the US with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), glycerin, and HydroCell technology - Allergan's proprietary sodium chloride (NaCl) free, glycerin-based solution that enables hydration and maintains the volume of cells on the ocular surface.
"We are pleased to expand our robust artificial tear portfolio with Refresh Relieva products as we continue to exemplify our commitment to innovation in eye care. This brand-new line provides doctors and patients with three unique options to treat patients' individual needs when it comes to dry, irritated eyes and contact lens dryness," said Jag Dosanjh, Senior Vice President, Allergan US Eye Care. "With Refresh Relieva for Contacts, contact lens patients now have a new option. As the number one selling brand in preservative-free artificial tears, it was also important to us to introduce Refresh Relieva in a new, convenient preservative-free bottle. Now patients can enjoy the convenience of a multidose bottle with all the benefits of being preservative-free."
Over 26 million people in the US suffer from symptoms of eye dryness, including irritation, burning, dryness, and discomfort. Eye dryness can be caused by advanced age, contact lens wear, certain medications, other medical conditions, or environmental factors. Studies show Refresh Relieva products improve the symptoms of eye dryness in patients, with a low incidence of blur upon installation.
70% of patients reported no blur when Refresh Relieva and Refresh Relieva for Contacts was first applied.
"As eye dryness varies for each patient, I'm excited to have three new artificial tear treatment options since we know that one size doesn't fit all for patients," said Milton Hom, OD. "Different patients have different needs and Refresh Relieva provides the diversity to satisfy more patients. With a low-blur formula and HydroCell technology Refresh Relieva will be my preferred artificial tear."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance